Fulcrum Therapeutics Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Fulcrum Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 34.8% bzw. 62.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 37.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -27.1% betragen.
Wichtige Informationen
34.8%
Wachstumsrate der Gewinne
37.20%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 14.5% |
| Wachstumsrate der Einnahmen | 62.8% |
| Zukünftige Eigenkapitalrendite | -27.09% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 08 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Analyseartikel • Apr 01
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. By way of example, Fulcrum...
Neues Narrativ • Mar 20
Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on small molecule treatments for genetically defined diseases, with an emphasis on sickle cell disease and hematologic conditions. What are the underlying business or industry changes driving this perspective?
Neues Narrativ • Mar 04
Oral Fetal Hemoglobin Induction Will Reshape Severe Sickle Cell Treatment Over The Long Term
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on developing oral fetal hemoglobin inducers for sickle cell disease and other hemoglobinopathies. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Feb 26
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion
Summary Fulcrum Therapeutics pivots to pociredir for severe sickle cell disease after discontinuing losmapimod. Pociredir’s Phase 1 PIONEER data shows 7/12 patients hitting the ≥20% HbF threshold, but mean HbF just misses the mark. FULC’s valuation is tied almost entirely to pociredir, with a risk-adjusted NPV of $136 million and $352.3 million in cash. I maintain a cautious 'Hold' rating; upside is limited by actual TAM and risk profile despite potential for accelerated approval. Read the full article on Seeking AlphaAnalyseartikel • Sep 25
We're Not Very Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Fulcrum Therapeutics...Analyseartikel • Apr 04
Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) is a stock...Analyseartikel • Dec 23
There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders have had their patience rewarded with a 34% share price jump in...Analyseartikel • Nov 08
We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analyseartikel • Sep 13
Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders that were waiting for something to happen have been dealt a...Seeking Alpha • Sep 12
Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Summary Fulcrum Therapeutics, Inc.'s stock plummeted over 60% after its lead candidate, losmapimod, failed to meet primary and secondary endpoints in a Phase 3 study for FSHD. Despite prior optimism and significant investments from Sanofi and positive analyst ratings, the REACH trial's results were disappointing, leading to the suspension of the losmapimod program. Fulcrum's management, facing leadership changes and a challenging market, will now focus on its other clinical-stage candidate, pociredir, for sickle cell disease. With a market cap of $550m and nearly $300m in cash, the future value of Fulcrum's pipeline remains uncertain amidst intense competition. Read the full article on Seeking AlphaAnalyseartikel • Jul 12
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Fulcrum...Analyseartikel • Feb 11
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analyseartikel • Oct 28
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analyseartikel • Jul 11
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analyseartikel • Nov 17
What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
The latest analyst coverage could presage a bad day for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ), with the analysts...Analyseartikel • Oct 18
We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyseartikel • Aug 13
Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Today is shaping up negative for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders, with the analysts delivering...Seeking Alpha • Aug 11
Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Fulcrum Therapeutics press release (NASDAQ:FULC): Q2 GAAP EPS of -$0.83 misses by $0.17. Revenue of $1.9M (-56.6% Y/Y) misses by $1.06M. As of June 30, 2022, cash, cash equivalents, and marketable securities were $169.0M, as compared to $218.2M as of December 31, 2021. Based on current operating plans, including successful implementation of the operational realignment, Fulcrum expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into mid-2024.Seeking Alpha • Jul 11
Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Fulcrum Therapeutics (NASDAQ:FULC) on Monday said its chief medical officer Christopher Morabito will be leaving the company effective July 13. FULC said its R&D president Judith Dunn will be the interim chief medical officer while the company searches for a new executive. FULC said Dunn had assumed direct oversight of all clinical activities and related functions. Prior to joining Fulcrum (FULC), Dunn had held multiple leadership positions including leading global clinical development for Roche (OTCQX:RHHBY) (OTCQX:RHHBF). FULC stock earlier closed -4.1% at $5.69.Seeking Alpha • Jul 05
Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Fulcrum Therapeutics (NASDAQ:FULC) said the first patient was dosed in a phase 3 trial of losmapimod to treat Facioscapulohumeral Muscular Dystrophy (FSHD). FSHD is a rare progressive disorder characterized by muscle weakness and wasting and initially affects the face, shoulder blades and upper arms. The study, dubbed REACH, will enroll ~230 adults at over 30 sites in North America and Europe and evaluate losmapimod, given orally as a 15-mg tablet twice a day, against placebo. The company said that a phase 2 trial, called ReDUX4, showed that losmapimod was superior to placebo and slowed disease progression and helped maintain function in adults with FSHD.Seeking Alpha • Jun 27
Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Fulcrum lost hugely this month after announcing data from an early Sickle Cell Disease trial. The other program is also beset with issues. This does not look attractive to us right now.Analyseartikel • May 10
These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
Market forces rained on the parade of Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders today, when the analysts...Analyseartikel • Apr 09
Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 43 | -76 | -63 | -81 | 6 |
| 12/31/2027 | N/A | -103 | -94 | -87 | 9 |
| 12/31/2026 | N/A | -87 | -87 | -84 | 9 |
| 3/31/2026 | N/A | -76 | -64 | -64 | N/A |
| 12/31/2025 | N/A | -75 | -60 | -60 | N/A |
| 9/30/2025 | N/A | -71 | -60 | -60 | N/A |
| 6/30/2025 | N/A | -73 | -65 | -65 | N/A |
| 3/31/2025 | 80 | -1 | 8 | 8 | N/A |
| 12/31/2024 | 80 | -10 | -2 | -2 | N/A |
| 9/30/2024 | 81 | -18 | -9 | -9 | N/A |
| 6/30/2024 | 82 | -20 | -13 | -12 | N/A |
| 3/31/2024 | 3 | -99 | -92 | -92 | N/A |
| 12/31/2023 | 3 | -97 | -91 | -91 | N/A |
| 9/30/2023 | 3 | -99 | -88 | -88 | N/A |
| 6/30/2023 | 3 | -98 | -93 | -92 | N/A |
| 3/31/2023 | 4 | -109 | -101 | -99 | N/A |
| 12/31/2022 | 6 | -110 | -99 | -97 | N/A |
| 9/30/2022 | 11 | -107 | -102 | -99 | N/A |
| 6/30/2022 | 14 | -104 | -96 | -94 | N/A |
| 3/31/2022 | 17 | -90 | -86 | -84 | N/A |
| 12/31/2021 | 19 | -81 | -80 | -78 | N/A |
| 9/30/2021 | 18 | -75 | -78 | -76 | N/A |
| 6/30/2021 | 15 | -73 | -60 | -58 | N/A |
| 3/31/2021 | 13 | -69 | -56 | -55 | N/A |
| 12/31/2020 | 9 | -71 | -55 | -54 | N/A |
| 9/30/2020 | 5 | -69 | -39 | -38 | N/A |
| 6/30/2020 | 3 | -68 | -48 | -47 | N/A |
| 3/31/2020 | 1 | -68 | -46 | -45 | N/A |
| 12/31/2019 | N/A | -90 | N/A | -39 | N/A |
| 9/30/2019 | N/A | -85 | N/A | -41 | N/A |
| 6/30/2019 | N/A | -79 | N/A | -32 | N/A |
| 3/31/2019 | N/A | -71 | N/A | -26 | N/A |
| 12/31/2018 | N/A | -39 | N/A | -23 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: FULC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: FULC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: FULC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: FULC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Hohe Wachstumseinnahmen: FULC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: FULC wird voraussichtlich in 3 Jahren unrentabel sein.
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/22 07:23 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Fulcrum Therapeutics, Inc. wird von 17 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |